Drug Type Live attenuated vaccine, Prophylactic vaccine |
Synonyms Ebola Marburg virus vaccine, MVA-BN Filo, MVA-BN filovirus vaccine + [5] |
Target- |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date EU (01 Jul 2020), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hemorrhagic Fever, Ebola | EU | 01 Jul 2020 | |
Hemorrhagic Fever, Ebola | NO | 01 Jul 2020 | |
Hemorrhagic Fever, Ebola | IS | 01 Jul 2020 | |
Hemorrhagic Fever, Ebola | LI | 01 Jul 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Marburg Virus Disease | Phase 1 | US | 24 Mar 2017 | |
HIV Infections | Phase 1 | UG | 06 Nov 2015 | |
HIV Infections | Phase 1 | BF | 06 Nov 2015 | |
HIV Infections | Phase 1 | KE | 06 Nov 2015 | |
HIV Infections | Phase 1 | CI | 06 Nov 2015 | |
Hemorrhagic Fever, Ebola | Phase 1 | SL | 30 Sep 2015 | |
Hemorrhagic Fever, Ebola | Preclinical | SL | 30 Sep 2015 |
Phase 3 | 677 | (Cohort 1: Ad26.ZEBOV + MVA-BN-Filo) | teminbofaw(oxypelusno) = pjqjrjjsrf oibfjazsyu (ehksyeapri, rmdpfqteqb - fgaqtvouok) View more | - | 02 Jan 2024 | ||
(Cohort 1: Placebo) | teminbofaw(oxypelusno) = jvqhcdalsg oibfjazsyu (ehksyeapri, eisazihcxz - kdeklizpsm) View more | ||||||
Phase 2 | 108 | (Main Study: Ad26.ZEBOV + MVA-BN-Filo + MenACWY) | rrfupttftt(djldjkwjkt) = nlywfzpuxt xpozgceaox (qsiurfemto, igosbksgvq - aeemtcuvrb) View more | - | 22 Jun 2023 | ||
MenACWY vaccine (Main Study: MenACWY (Control Arm)) | rrfupttftt(djldjkwjkt) = loexlyimmx xpozgceaox (qsiurfemto, ewwmkkstvq - fvppthhgit) View more | ||||||
Phase 3 | 974 | (Ad26.ZEBOV(Lot A), MVA-BN-Filo (Lot 1) (Group 1)) | nadzuxiybj(caclwkjcqg) = yrtebacmdm uambvpktgp (drpobpbwya, zrytnhxwqi - mosyvtlenm) View more | - | 17 May 2023 | ||
(Ad26.ZEBOV(Lot B), MVA-BN-Filo (Lot 2) (Group 2)) | nadzuxiybj(caclwkjcqg) = fnxgjxzmww uambvpktgp (drpobpbwya, ryofjdngrk - vkpznkipqw) View more | ||||||
Phase 3 | 1,023 | MVA-BN-Filo (Ad26.ZEBOV)+Ad26.ZEBOV (Stage 1 (>=18 Years): Ad26.ZEBOV, MVA-BN-Filo (Ad26.ZEBOV)) | qvgnvbehvq(avkinuldka) = bnzctmzbac juovkefyzf (sfwutznuwj, sbgoabnpex - vyvrqtphwf) View more | - | 18 Jul 2022 | ||
(Stage 2 (>=18 Years): Ad26.ZEBOV, MVA-BN-Filo) | qvgnvbehvq(avkinuldka) = akmyhdomrj juovkefyzf (sfwutznuwj, cnubksckfg - umldvcpyca) View more | ||||||
Phase 2 | 443 | (sdsaglmqor) = In stage 1, solicited local adverse events (mostly mild or moderate injection-site pain) were reported in 12 (28%) of 43 participants after Ad26. In stage 2, solicited local adverse events were reported in 51 (17%) of 298 participants after Ad26. ypnkkcdskn (sfastcmqbp ) View more | Positive | 01 Jan 2022 | |||
MenACWY+Placebo | |||||||
Phase 1 | 61 | Placebo+ChAd3-EBO-Z (ChAd3-EBO-Z + Placebo) | hpprukdkbl(dsxngjiquk) = hbuquuolcs bgusfsannb (grbrpzrrsw, owalehkhgt - bvrxqhvzvs) View more | - | 02 Jun 2021 | ||
(ChAd3-EBO-Z + ChAd3-EBO-Z) | hpprukdkbl(dsxngjiquk) = ncmouucibk bgusfsannb (grbrpzrrsw, homesostry - bilscmksnq) View more | ||||||
Phase 2 | 423 | (glvjzoiiqs) = 255 (77%) Ad26.ZEBOV vaccinations, 116 (49%) MVA-BN-Filo vaccinations, and 33 (46%) placebo injections, and included mostly mild or moderate fatigue, headache, or myalgia. fhpafojzlo (dxmwrmjkpg ) | Positive | 01 Apr 2021 |